Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | APP | P05067 | 1/20 | 0.63 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.63 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.63 |
| ▸ | F7 | P08709 | 1/20 | 0.61 |
| ▸ | F3 | P13726 | 1/20 | 0.61 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.61 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.61 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.61 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.61 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.61 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.61 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Niacin SCHEMBL15017991 | 0.98 | ALDH1A1 (0.61) | ALDH1A1GAAAPPHCAR3HCAR2 | |
| Niacin SCHEMBL3498987 | 0.96 | ALDH1A1 (0.63) | ALDH1A1GAAAPPHCAR3HCAR2 | |
| Niacin SCHEMBL587526 | 0.96 | ALDH1A1 (0.63) | ALDH1A1GAAAPPHCAR3HCAR2 | |
| Niacin SCHEMBL517582 | 0.96 | ALDH1A1 (0.63) | ALDH1A1GAAAPPHCAR3HCAR2 | |
| Niacin SCHEMBL25269786 | 0.96 | ALDH1A1 (0.63) | ALDH1A1GAAAPPHCAR3HCAR2 | |
| Niacin SCHEMBL23780930 | 0.96 | ALDH1A1 (0.63) | ALDH1A1GAAAPPHCAR3HCAR2 | |
| Niacin SCHEMBL308681 | 0.96 | ALDH1A1 (0.63) | ALDH1A1GAAAPPHCAR3HCAR2 | |
| Niacin SCHEMBL10357700 | 0.96 | ALDH1A1 (0.63) | ALDH1A1GAAAPPHCAR3HCAR2 | |
| Niacin SCHEMBL1943861 | 0.96 | ALDH1A1 (0.63) | ALDH1A1GAAAPPHCAR3HCAR2 | |
| Niacin SCHEMBL987479 | 0.96 | ALDH1A1 (0.63) | ALDH1A1GAAAPPHCAR3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 882 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| EP-3485908-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | MEREO BIOPHARMA 5 INC (US) | 2021-08-18 | — | — | EP | claimed |
| US-10335403-B2 | Niacin formulation | ZEENAR ENTERPRISE PTY LTD (AU) | 2019-07-02 | — | — | US | claimed |
| US-20190015403-A1 | NIACIN FORMULATION | Zeenar Enterprises Pty Ltd. (AU) | 2019-01-17 | — | — | US | claimed |
| EP-3072526-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | ONCOMED PHARM INC (US) | 2018-09-26 | — | — | EP | claimed |
| US-9982042-B2 | Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent | ONCOMED PHARMACEUTICALS, INC. (US) | 2018-05-29 | — | — | US | claimed |
| US-20170166632-A1 | Therapeutic Combination and Methods of Treatment With A DLL4 Antagonist and an Anti-Hypertensive Agent | ONCOMED PHARMACEUTICALS, INC. | 2017-06-15 | — | — | US | claimed |
| US-20160367645-A1 | LYSOSOMAL ACID LIPASE THERAPY FOR NAFLD AND RELATED DISEASES | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2016-12-22 | — | — | US | claimed |
| US-9511139-B2 | Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent | ONCOMED PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | claimed |
| EP-3072526-A1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | Oncomed Pharmaceuticals, Inc. (US) | 2016-09-28 | — | — | EP | claimed |
| EP-0969837-A1 | NICOTINIC ACID COMPOSITIONS FOR TREATING HYPERLIPIDEMIA AND RELATED METHODS THEREFOR | KOS PHARMACEUTICALS, INC. (US) | 2000-01-12 | — | — | EP | claimed |
| WO-1999006052-A9 | METHODS OF PRETREATING HYPERLIPIDEMIC INDIVIDUALS WITH A FLUSH INHIBITING AGENT PRIOR TO THE START OF SINGLE DAILY DOSE NICOTINIC ACID THERAPY TO REDUCE FLUSHING PROVOKED BY NICOTINIC ACID | KOS PHARMA INC (US) | 1999-04-29 | — | — | WO | claimed |
| WO-1999006052-A1 | METHODS OF PRETREATING HYPERLIPIDEMIC INDIVIDUALS WITH A FLUSH INHIBITING AGENT PRIOR TO THE START OF SINGLE DAILY DOSE NICOTINIC ACID THERAPY TO REDUCE FLUSHING PROVOKED BY NICOTINIC ACID | KOS PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | claimed |
| WO-1999006035-A2 | COMBINATIONS OF HMG-CoA REDUCTASE INHIBITORS AND NICOTINIC ACID COMPOUNDS AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT | KOS PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | claimed |
| WO-1998039002-A1 | NICOTINIC ACID COMPOSITIONS FOR TREATING HYPERLIPIDEMIA AND RELATED METHODS THEREFOR | KOS PHARMACEUTICALS, INC. (US) | 1998-09-11 | — | — | WO | claimed |
| EP-0643965-A1 | Nicotinic acid compositions for treating hyperlipidemia | KOS PHARMACEUTICALS, INC. (US) | 1995-03-22 | — | — | EP | claimed |
| CN-1079650-A | The new purposes of nicotinic acid and derivant thereof | QIU BOLING (CN) | 1993-12-22 | — | — | CN | claimed |
| US-5087538-A | Toner and imaging processes | XEROX CORPORATION (US) | 1992-02-11 | — | — | US | claimed |
| US-5075185-A | IMAGING PROCESS COMPRISING TRI-LEVEL IMAGING AREA AND AN ALUMINUM COMPLEX CHARGE ENHANCING ADDITIVE | XEROX CORPORATION (US) | 1991-12-24 | — | — | US | claimed |
| US-4789615-A | Toner compositions with nicotinate charge enhancing additives | XEROX CORPORATION (US) | 1988-12-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367645-A1 | LYSOSOMAL ACID LIPASE THERAPY FOR NAFLD AND RELATED DISEASES | LIPC, PNLIP, LIPA | ALDH1A1 1049/4885GAA 6/4885APP 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.